Dr. Bonnett had the opportunity to present at the Ketamine Research Institute 2017 conference in San Francisco. As always, this is an amazing conference that brings together some of the leaders in ketamine research and clinical care. Dr. Bonnett discussed the interim results of our research study on ketamine for the treatment of Post-Traumatic Stress Disorder (PTSD). We have treated 17 of the approved 30 veterans and have seen some promising results. We hope to have the study wrapped up in the next three months.

He also discussed Klarisana’s recent interaction with the Texas Medical Board where we successfully argued that what centers such as Klarisana offer is not Office-Based Anesthesia (OBA) but rather Ketamine for Non-Anesthetic Indications (KNAI). We feel that the desire of some clinicians to get this treatment designated as OBA is simply a tactic to drive up costs and limit access to ketamine therapy.